Global clinical research organization Emmes has launched Orphan Reach, a new rare disease centre combining the expertise of Orphan Reach, a UK-based speciality CRO acquired by Emmes in May 2021, and Emmes’ biostatistics, data management, and global clinical trial execution capabilities, enabling the centre to function as a full, end-to-end services organization.

The expanded Orphan Reach is dedicated to the advancement of rare disease research by providing specialized clinical trial design and execution capabilities. Emmes expects the Orphan Reach clinical study portfolio to double over the next 12 months, with Emmes’ joint services and technologies bringing new capabilities to the expanding rare disease drug development market.

The newly dedicated centre will be launched at the World Orphan Drug Congress in Barcelona, Spain on November 15. In addition to Dr. Clemons, the centre will be led by a team of senior industry executive experts in rare diseases including Thomas Ogorka, Managing Director, Nazira Maruf, Vice President of Project Management, and Dr Traci Clemons, Chief Research Officer.